ClinicalTrials.gg
CompletedNCT01436396Updated Mar 25, 2022Results posted

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

A Phase 3 interventional study of Live, attenuated dengue serotype 1, 2, 3, and 4 virus and Yellow fever vaccine in Dengue, Dengue Hemorrhagic Fever and Yellow Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 2 sites in 2 countries. Open to participants aged 12 Months to 13 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-25.

Primary conditionSevere DengueRegistry: DengueReclassifiedWhy we changed it
Registry
Dengue — the first condition term the registry derived for this study.
ClinicalTrials.gg
Severe Dengue
Why
  1. The study's listed conditions name Severe Dengue, a narrower term within Dengue.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
792
Allocation
Randomized
Ages
12 Months to 13 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Severe Dengue by Sanofi — none open to participants now, none under way, none of them phase 3. Severe Dengue · Sanofi.

Enrollment
6th of 26
792 · median 345
Started
2011
with 5 others
Phase 3
9 of 29
none open now
Registered
16th of 29
by date

Among the 29 studies in Severe Dengue by Sanofi, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2011, is one of 9 in phase 3, and was the 16th registered.

Severe Dengue

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

Browse Severe Dengue studies →

Open to participants now

None of the 29 studies in Severe Dengue by Sanofi is open now. The open studies under Severe Dengue, anywhere →

Who these studies take

Of the 4 Severe Dengue studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 12 Months to 13 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Severe Dengue by Sanofi as a file.
02

Study summary

The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration.

Primary Objective:

  • To demonstrate the non-inferiority of the immune response against Yellow Fever (YF) in flavivirus (FV) non-immune subjects at baseline receiving one dose of Stamaril vaccine administered concomitantly with the first dose of CYD dengue vaccine compared to participants receiving one dose of Stamaril vaccine concomitantly with placebo.

Secondary Objectives:

  • To assess the non-inferiority of YF immune response 28 days post-Stamaril vaccination based on seroconversion rates regardless of the FV status of participants at baseline.
  • To describe the YF immune response 28 days post-Stamaril vaccination in both groups.
  • To describe the antibody (Ab) response to each dengue virus serotype 28 days post CYD dengue vaccine (Visit [V] 05 and V07), following CYD dengue vaccine Dose 1 and Dose 2 from Group 2 versus following CYD dengue vaccine Dose 2 and Dose 3 for Group 1 (effect of YF vaccination).
  • To describe the safety of Stamaril vaccine administered concomitantly with the first dose of CYD dengue vaccine, or Stamaril administered concomitantly with placebo.
  • To describe the safety of CYD dengue vaccine after the first dose of CYD dengue vaccine administered concomitantly with Stamaril vaccine or CYD vaccine administered alone.
  • To describe the safety of the CYD dengue vaccine in all participants after each dose.
Read the detailed description

All participants received a total of 9 injections during the study. Vaccine immunogenicity assessments for dengue neutralizing antibodies was performed in a randomized subset of participants. All participants were followed-up for safety during the study and for 6 months after the last CYD dengue vaccination.

03

Conditions studied

  • Dengue
  • Dengue Hemorrhagic Fever
  • Yellow Fever

Browse trials for

Keywords

  • Dengue
  • Dengue Hemorrhagic Fever
  • CYD Dengue Vaccines
  • Yellow Fever
  • Stamaril®
  • Flavivirus Infections
04

In context

Severe Dengue Reclassified

65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.

This study's enrollment of 792 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.

Browse Severe Dengue studies →

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Compared within Severe Dengue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dengue. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Months to 13 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 12 to 13 months on the day of inclusion.
  • Born at full term of pregnancy (>=37 weeks) and with a birth weight >=2.5 kg as reported by the parent/legally acceptable representative.
  • Participant in good health, based on medical history and physical examination.
  • Participant had completed his/her vaccination schedule according to the official immunization calendar of Colombia and/or Peru, respectively.
  • form had been signed and dated by the parent(s) or other legally acceptable representative (and by 2 independent witnesses if required by local regulations).
  • Participant and parent/legally acceptable representative/tutor able to attend all scheduled visits and to comply with all trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination.
  • Planned participation in another clinical trial during the present trial period.
  • Planned receipt of any vaccine in the 4 weeks following first trial vaccination.
  • Previous vaccination against YF, hepatitis A, or measles, mumps and rubella.
  • Receipt of blood or blood-derived products in the past 3 months which might interfere with assessment of the immune response.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 weeks or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • Personal known seropositivity for (HIV) as reported by the parent/legally acceptable representative.
  • History of previous maternal vaccination against YF as reported by the parent/legally acceptable representative.
  • Personal history of YF or dengue infection/disease as reported by the parent/legally acceptable representative.
  • Known systemic to any of the vaccine components of the vaccines that were used in the trial, or history of a life-threatening reaction to the vaccines used in the trial or to vaccines containing any of the same substances.
  • History of to receipt of vaccines containing components of Stamaril® (yellow fever vaccine), measles, mumps and rubella vaccine, hepatitis A vaccine, pneumococcal conjugated vaccine or of diphtheria (D) toxoid, tetanus (T) toxoid, pertussis toxoid (PT), filamentous hemagglutinin (FHA), polyribosylribitol phosphate (PRP) and polio or other diphtheria, tetanus and pertussis vaccine (e.g., DTwP).
  • Thrombocytopenia, as reported by the parent/legally acceptable representative.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular (IM) vaccination.
  • History of central nervous system disorder or disease, including seizures.
  • Personal history of thymic pathology (e.g., thymoma), and/or thymectomy.
  • Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
  • Identified as a child (adopted or natural) of the Investigator or of employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
792 participants (actual)

Study arms

  • Experimental
    CYD Dengue Vaccine Group

    Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month \[M\] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).

    Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus · Biological: Yellow fever vaccine · Biological: Measles, mumps, and rubella (MMR) vaccine · Biological: Pneumococcal Conjugated Vaccine · Biological: Hepatitis A Pediatric Vaccine · Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine

  • Experimental
    Placebo Group

    Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).

    Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus · Biological: Yellow Fever Vaccine · Biological: Placebo (NaCl) · Biological: Measles, mumps, and rubella vaccine · Biological: Pneumococcal Conjugated Vaccine · Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine · Biological: Hepatitis A Pediatric Vaccine

Interventions

  • BiologicalLive, attenuated dengue serotype 1, 2, 3, and 4 virus

    0.5 mL, subcutaneous at age 12, 18, and 24 months

    Also known as: CYD Dengue Vaccine

  • 0.5 mL subcutaneous in the deltoid at age 12 to 13 months.

    Also known as: Stamaril®

  • BiologicalMeasles, mumps, and rubella (MMR) vaccine

    Drug page: Measles-Mumps-Rubella Vaccine

    0.5 mL, subcutaneous at age 12 to 13 months.

    Also known as: MMR vaccine

  • BiologicalPneumococcal Conjugated Vaccine

    0.5 mL, intramuscular at age 13 to 14 months

  • BiologicalHepatitis A Pediatric Vaccine

    0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months

  • BiologicalDiphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine

    0.5 mL, intramuscular at age 19 to 20 months

    Also known as: DTaP IPV//Hib Vaccine

  • BiologicalLive, attenuated dengue serotype 1, 2, 3, and 4 virus

    0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months

    Also known as: CYD dengue vaccine

  • 0.5 mL, subcutaneous at age 12 to 13 months

    Also known as: Stamaril®

  • BiologicalPlacebo (NaCl)

    0.5 mL, subcutaneous at age 12 to 13 months

    Also known as: NaCl 0.9%

  • BiologicalMeasles, mumps, and rubella vaccine

    Drug page: Measles-Mumps-Rubella Vaccine

    0.5 mL, subcutaneous at age 13 to 14 months

    Also known as: MMR vaccine

  • BiologicalPneumococcal Conjugated Vaccine

    0.5 mL, intramuscular at age 13 to 14 months

  • BiologicalDiphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine

    0.5 mL, intramuscular at age 19 to 20 months

    Also known as: DTaP IPV//Hib Vaccine

  • BiologicalHepatitis A Pediatric Vaccine

    0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months

07

What researchers measure

Primary outcomes

  1. Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dilution \[dil\]) in flavivirus non-immune participants (defined as those with YF antibodies \<10 \[1/dil\] for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus).

    Time frame: 28 days Post-Injection 1

Secondary outcomes

  1. Percentage of All Participants With Seroconversion Against YF Antigen After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>= 10 (1/dil) in participants YF-seronegative at baseline or 4-fold increase from pre- to post-YF antibody titers in participants YF-seropositive at baseline.

    Time frame: 28 days Post-Injection 1

  2. Geometric Mean Titers (GMTs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    GMTs against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.

    Time frame: Pre-Injection 1 and 28-days Post-Injection 1

  3. Geometric Mean Titer Ratios (GMTRs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    GMTs ratios against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.

    Time frame: Pre-Injection 1 and 28- days Post-Injection 1

  4. Percentage of All Participants With YF Antibody Titers of >=10 (1/Dil) Before and After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dil) regardless of the flavivirus status of participants at baseline.

    Time frame: Pre-Injection 1 and 28-days Post-Injection 1

  5. GMTs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue plaque reduction neutralization test (PRNT) assay.

    Time frame: Pre-Injection 1 and 28-days Post-Injections 2 and 3

  6. GMTRs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    GMTRs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.

    Time frame: Pre-Injection 1 and 28-days Post-Injections 2 and 3

  7. Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. Seroconversion was defined as antibody titers \>= 10 (1/dil) against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains.

    Time frame: Pre-Injection 1 and 28-days Post-Injections 2 and 3

  8. Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against at Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    Neutralizing antibodies against at least 1, 2, 3, or 4 serotypes (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.

    Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3

  9. GMTs of Dengue Virus Antibodies of FV Immune Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV immune participants at baseline were defined as those participants with \>= 10 (1/dil) for at least 1 serotype with the parental dengue virus strain or for YF virus.

    Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3

  10. GMTs of Dengue Virus Antibodies of FV-Non Immune (Naïve) Participants Following Vaccination With YF Vaccine Non Immune (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-non-immune participants at baseline were defined as those participants with \<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.

    Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3

  11. Percentage of FV-immune Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-immune participants at baseline were defined as those participants with \>= 10 (1/dil) for at least 1 serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strain or for YF virus.

    Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3

  12. Percentage of FV Non-immune (Naïve) Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With the Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV non-immune participants at baseline were defined as those participants with \<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.

    Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3

  13. Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Injection With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

    Solicited injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost and Irritability. Grade 3 Solicited injection site reactions: Tenderness: cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling: \>=50 millimeter (mm). Grade 3 Solicited systemic reactions: Fever: \>39.5°celsius; Vomiting: \>= episodes per 24 hours or requiring parenteral hydration; Crying abnormal: \>3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite lost: refuses \>=3 feeds/meals or refuses most feeds/meals; Irritability: inconsolable. Solicited Injection site reaction were reported separately for Stamaril®, CYD and placebo vaccine.

    Time frame: Day 0 up to 14 days post any Inj., Post Inj. 1, Post Inj. 2 and Post Inj. 3

08

Results

Posted Jul 29, 2019
Limitations and caveats
None reported

Participant flow

Study participants were enrolled from 07 September 2011 to 08 March 2012 at 2 clinical sites (1 in Colombia and 1 in Peru).

Participant flow — Overall Study
MilestoneCYD Dengue Vaccine GroupPlacebo Group
Started396396
Vaccinated394393
Completed364354
Not completed3242
Withdrew: Protocol violation75
Withdrew: Adverse event12
Withdrew: Withdrawal by subject1929
Withdrew: Serious adverse event23
Withdrew: Lost to follow-up33

Outcome measures

PrimaryPercentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dilution \[dil\]) in flavivirus non-immune participants (defined as those with YF antibodies \<10 \[1/dil\] for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus).

Time frame:
28 days Post-Injection 1
Reported as:
Number · Percentage of participants
Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Percentage of participantsCYD Dengue Vaccine GroupPlacebo Group
Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo100.099.7
Statistical analysis
  • CYD Dengue Vaccine Group vs Placebo Group · Difference in percentage: 0.334 · 95% CI -0.976 to 1.87
SecondaryPercentage of All Participants With Seroconversion Against YF Antigen After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>= 10 (1/dil) in participants YF-seronegative at baseline or 4-fold increase from pre- to post-YF antibody titers in participants YF-seropositive at baseline.

Time frame:
28 days Post-Injection 1
Reported as:
Number · Percentage of participants
Percentage of All Participants With Seroconversion Against YF Antigen After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Percentage of participantsCYD Dengue Vaccine GroupPlacebo Group
Percentage of All Participants With Seroconversion Against YF Antigen After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo98.799.7
Statistical analysis
  • CYD Dengue Vaccine Group vs Placebo Group · Difference in percentage: -1.06 · 95% CI -2.81 to 0.383
SecondaryGeometric Mean Titers (GMTs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

GMTs against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.

Time frame:
Pre-Injection 1 and 28-days Post-Injection 1
Reported as:
Geometric mean · Titers (1/dilution)
Geometric Mean Titers (GMTs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Titers (1/dilution)CYD Dengue Vaccine GroupPlacebo Group
Pre-Injection 15.64 (5.41 to 5.89)5.67 (5.42 to 5.93)
Post-Injection 1369 (322 to 423)423 (375 to 478)
SecondaryGeometric Mean Titer Ratios (GMTRs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

GMTs ratios against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.

Time frame:
Pre-Injection 1 and 28- days Post-Injection 1
Reported as:
Geometric mean · Ratio
Geometric Mean Titer Ratios (GMTRs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
RatioCYD Dengue Vaccine GroupPlacebo Group
Geometric Mean Titer Ratios (GMTRs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo35.1 (30.5 to 40.4)39.8 (35.3 to 45.0)
SecondaryPercentage of All Participants With YF Antibody Titers of >=10 (1/Dil) Before and After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dil) regardless of the flavivirus status of participants at baseline.

Time frame:
Pre-Injection 1 and 28-days Post-Injection 1
Reported as:
Number · Percentage of participants
Percentage of All Participants With YF Antibody Titers of >=10 (1/Dil) Before and After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Percentage of participantsCYD Dengue Vaccine GroupPlacebo Group
Pre-Injection 19.09.0
Post-Injection 199.599.7
SecondaryGMTs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue plaque reduction neutralization test (PRNT) assay.

Time frame:
Pre-Injection 1 and 28-days Post-Injections 2 and 3
Reported as:
Geometric mean · Titers (1/dilution)
GMTs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Titers (1/dilution)CYD Dengue Vaccine GroupPlacebo Group
Serotype 1; Pre-Injection 15.08 (4.92 to 5.25)5.00 (5.00 to 5.00)
Serotype 1; Post-Injection 247.3 (38.9 to 57.5)11.8 (9.82 to 14.1)
Serotype 1; Post-Injection 389.0 (76.4 to 104)61.3 (52.5 to 71.5)
Serotype 2; Pre-Injection 15.10 (4.96 to 5.23)5.00 (5.00 to 5.00)
Serotype 2; Post-Injection 295.5 (78.0 to 117)41.1 (33.2 to 51.0)
Serotype 2; Post-Injection 3173 (142 to 211)150 (127 to 177)
Serotype 3; Pre-Injection 15.05 (4.95 to 5.16)5.18 (5.00 to 5.37)
Serotype 3; Post-Injection 2118 (101 to 137)43.4 (36.0 to 52.3)
Serotype 3; Post-Injection 3181 (158 to 207)155 (136 to 176)
Serotype 4; Pre-Injection 15.00 (5.00 to 5.00)5.05 (4.96 to 5.14)
Serotype 4; Post-Injection 268.1 (54.6 to 84.9)29.8 (22.1 to 40.2)
Serotype 4; Post-Injection 374.0 (61.3 to 89.4)74.6 (62.5 to 89.1)
SecondaryGMTRs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

GMTRs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.

Time frame:
Pre-Injection 1 and 28-days Post-Injections 2 and 3
Reported as:
Geometric mean · Titer ratios
GMTRs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Titer ratiosCYD Dengue Vaccine GroupPlacebo Group
Serotype 1; Post-Inj.2/Pre-Inj. 14.78 (3.91 to 5.84)1.15 (0.973 to 1.37)
Serotype 1; Post-Inj.3/Pre-Inj. 18.82 (7.55 to 10.3)6.14 (5.26 to 7.18)
Serotype 2; Post-Inj.2/Pre-Inj. 19.55 (7.75 to 11.8)3.86 (3.15 to 4.72)
Serotype 2; Post-Inj.3/Pre-Inj. 116.7 (13.7 to 20.4)15.2 (12.8 to 18.1)
Serotype 3; Post-Inj.2/Pre-Inj. 111.6 (9.98 to 13.5)4.16 (3.46 to 5.00)
Serotype 3; Post-Inj.3/Pre-Inj. 118.0 (15.6 to 20.8)15.4 (13.5 to 17.6)
Serotype 4; Post-Inj.2/Pre-Inj. 16.82 (5.44 to 8.55)2.89 (2.15 to 3.89)
Serotype 4; Post-Inj.3/Pre-Inj. 17.26 (6.02 to 8.77)7.44 (6.24 to 8.88)
SecondaryPercentage of Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. Seroconversion was defined as antibody titers \>= 10 (1/dil) against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains.

Time frame:
Pre-Injection 1 and 28-days Post-Injections 2 and 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Percentage of participantsCYD Dengue Vaccine GroupPlacebo Group
Serotype 1; Pre-Injection 10.90.0
Serotype 1; Post-Injection 292.051.3
Serotype 1; Post-Injection 3100.097.2
Serotype 2; Pre-Injection 11.80.0
Serotype 2; Post-Injection 297.386.7
Serotype 2; Post-Injection 3100.0100.0
Serotype 3; Pre-Injection 10.93.7
Serotype 3; Post-Injection 2100.090.3
Serotype 3; Post-Injection 3100.0100.0
Serotype 4; Pre-Injection 10.00.9
Serotype 4; Post-Injection 291.268.1
Serotype 4; Post-Injection 397.398.1
SecondaryPercentage of Participants With Antibody Titer >= 10 (1/Dil) Against at Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

Neutralizing antibodies against at least 1, 2, 3, or 4 serotypes (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.

Time frame:
Pre-Injection 1 and 28 days Post-Injections 2 and 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against at Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Percentage of participantsCYD Dengue Vaccine GroupPlacebo Group
At least 1 serotype; Pre-Injection 13.64.5
At least 1 serotype; Post-Injection 2100.093.8
At least 1 serotype; Post-Injection 3100.0100.0
At least 2 serotypes; Pre-Injection 10.00.0
At least 2 serotypes; Post-Injection 2100.087.6
At least 2 serotypes; Post-Injection 3100.0100.0
At least 3 serotypes; Pre-Injection 10.00.0
At least 3 serotypes; Post-Injection 294.773.5
At least 3 serotypes; Post-Injection 3100.098.1
All 4 serotypes; Pre-Injection 10.00.0
All 4 serotypes; Post-Injection 285.841.6
All 4 serotypes; Post-Injection 397.397.2
SecondaryGMTs of Dengue Virus Antibodies of FV Immune Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV immune participants at baseline were defined as those participants with \>= 10 (1/dil) for at least 1 serotype with the parental dengue virus strain or for YF virus.

Time frame:
Pre-Injection 1 and 28 days Post-Injections 2 and 3
Reported as:
Geometric mean · Titers (1/dilution)
GMTs of Dengue Virus Antibodies of FV Immune Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Titers (1/dilution)CYD Dengue Vaccine GroupPlacebo Group
Serotype 1; Pre-Injection 15.96 (4.01 to 8.87)5.00 (5.00 to 5.00)
Serotype 1; Post-Injection 252.5 (25.0 to 110)17.0 (7.63 to 38.0)
Serotype 1; Post-Injection 381.7 (47.3 to 141)59.5 (44.6 to 79.5)
Serotype 2; Pre-Injection 16.14 (4.50 to 8.38)5.00 (5.00 to 5.00)
Serotype 2; Post-Injection 272.4 (47.4 to 111)74.3 (27.6 to 200)
Serotype 2; Post-Injection 3110 (75.5 to 160)133 (95.7 to 186)
Serotype 3; Pre-Injection 15.74 (4.15 to 7.94)6.75 (5.05 to 9.03)
Serotype 3; Post-Injection 2102 (54.8 to 189)95.8 (61.3 to 150)
Serotype 3; Post-Injection 3143 (89.7 to 227)126 (91.7 to 173)
Serotype 4; Pre-Injection 15.00 (5.00 to 5.00)5.41 (4.55 to 6.43)
Serotype 4; Post-Injection 287.1 (36 to 210)109 (44.7 to 265)
Serotype 4; Post-Injection 377.1 (24.0 to 248)74.3 (40.9 to 135)
SecondaryGMTs of Dengue Virus Antibodies of FV-Non Immune (Naïve) Participants Following Vaccination With YF Vaccine Non Immune (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-non-immune participants at baseline were defined as those participants with \<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.

Time frame:
Pre-Injection 1 and 28 days Post-Injections 2 and 3
Reported as:
Geometric mean · Titers (1/dilution)
GMTs of Dengue Virus Antibodies of FV-Non Immune (Naïve) Participants Following Vaccination With YF Vaccine Non Immune (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Titers (1/dilution)CYD Dengue Vaccine GroupPlacebo Group
Serotype 1; Pre-Injection 15.00 (5.00 to 5.00)5.00 (5.00 to 5.00)
Serotype 1; Post-Injection 245.9 (37.0 to 57.0)11.4 (9.42 to 13.7)
Serotype 1; Post-Injection 386.6 (73.0 to 103)61.8 (51.5 to 74.3)
Serotype 2; Pre-Injection 15.00 (5.00 to 5.00)5.00 (5.00 to 5.00)
Serotype 2; Post-Injection 299.0 (78.0 to 126)39.0 (31.4 to 48.5)
Serotype 2; Post-Injection 3174 (139 to 218)157 (129 to 192)
Serotype 3; Pre-Injection 15.00 (5.00 to 5.00)5.00 (5.00 to 5.00)
Serotype 3; Post-Injection 2118 (101 to 139)37.9 (30.8 to 46.8)
Serotype 3; Post-Injection 3184 (158 to 214)160 (138 to 187)
Serotype 4; Pre-Injection 15.00 (5.00 to 5.00)5.00 (5.00 to 5.00)
Serotype 4; Post-Injection 266.4 (51.8 to 85.1)24.0 (17.4 to 33.2)
Serotype 4; Post-Injection 373.0 (60.0 to 88.7)72.2 (59.1 to 88.1)
SecondaryPercentage of FV-immune Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-immune participants at baseline were defined as those participants with \>= 10 (1/dil) for at least 1 serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strain or for YF virus.

Time frame:
Pre-Injection 1 and 28 days Post-Injections 2 and 3
Reported as:
Number · percentage of participants
Percentage of FV-immune Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
percentage of participantsCYD Dengue Vaccine GroupPlacebo Group
Serotype 1; Pre-Injection 110.00.0
Serotype 1; Post-Injection 290.057.1
Serotype 1; Post-Injection 3100.0100.0
Serotype 2; Pre-Injection 120.00.0
Serotype 2; Post-Injection 2100.092.9
Serotype 2; Post-Injection 3100.0100.0
Serotype 3; Pre-Injection 112.530.8
Serotype 3; Post-Injection 2100.0100.0
Serotype 3; Post-Injection 3100.0100.0
Serotype 4; Pre-Injection 10.07.7
Serotype 4; Post-Injection 290.092.9
Serotype 4; Post-Injection 388.9100.0
SecondaryPercentage of FV Non-immune (Naïve) Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With the Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV non-immune participants at baseline were defined as those participants with \<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.

Time frame:
Pre-Injection 1 and 28 days Post-Injections 2 and 3
Reported as:
Number · Percentage of participants
Percentage of FV Non-immune (Naïve) Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With the Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Percentage of participantsCYD Dengue Vaccine GroupPlacebo Group
Serotype 1; Pre-Injection 10.00.0
Serotype 1; Post-Injection 292.651.1
Serotype 1; Post-Injection 3100.096.5
Serotype 2; Pre-Injection 10.00.0
Serotype 2; Post-Injection 296.886.7
Serotype 2; Post-Injection 3100.0100.0
Serotype 3; Pre-Injection 10.00.0
Serotype 3; Post-Injection 2100.087.8
Serotype 3; Post-Injection 3100.0100.0
Serotype 4; Pre-Injection 10.00.0
Serotype 4; Post-Injection 290.463.3
Serotype 4; Post-Injection 397.897.7
SecondaryPercentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Injection With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo

Solicited injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost and Irritability. Grade 3 Solicited injection site reactions: Tenderness: cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling: \>=50 millimeter (mm). Grade 3 Solicited systemic reactions: Fever: \>39.5°celsius; Vomiting: \>= episodes per 24 hours or requiring parenteral hydration; Crying abnormal: \>3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite lost: refuses \>=3 feeds/meals or refuses most feeds/meals; Irritability: inconsolable. Solicited Injection site reaction were reported separately for Stamaril®, CYD and placebo vaccine.

Time frame:
Day 0 up to 14 days post any Inj., Post Inj. 1, Post Inj. 2 and Post Inj. 3
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Injection With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Percentage of participantsCYD Dengue Vaccine GroupPlacebo Group
Inj. site Tenderness for Stamaril®; Post-Any Inj.25.417.6
Grd 3 Inj. site Tenderness, Stamaril®;Post-Any Inj0.30.3
Inj. site Tenderness for CYD dengue;Post-Any Inj.36.528.9
Grd 3 Inj site Tenderness, CYDdengue;Post-Any Inj0.30.0
Inj. site Tenderness for placebo; Post-Any Inj.—19.7
Grd 3 Inj. site Tenderness, placebo;Post-Any Inj.—0.3
Inj. site Erythema for Stamaril®; Post-Any Inj.8.39.8
Grd 3 Inj. site Erythema, Stamaril®;Post-Any Inj.0.00.0
Inj. site Erythema for CYD dengue;Post-Any Inj.12.78.8
Grd 3 Inj. site Erythema, CYD dengue;Post-Any Inj0.00.0
Inj. site Erythema for placebo; Post-Any Inj.—10.9
Grd 3 Inj. site Erythema for placebo; Post-Any Inj—0.0
Inj. site Swelling for Stamaril®; Post-Any Inj.4.74.4
Grd 3 Inj. site Swelling, Stamaril®; Post-Any Inj.0.00.0
Inj. site Swelling for CYD dengue; Post-Any Inj.7.56.1
Grd 3 Inj. site Swelling, CYD dengue; Post-Any Inj0.00.0
Inj. site Swelling for placebo; Post-Any inj.—4.9
Grd 3 Inj. site Swelling for placebo; Post-Any Inj—0.0
Inj. site Tenderness for Stamaril®; Post-Inj. 125.417.6
Grd 3 Inj. site Tenderness, Stamaril®; Post-Inj. 10.30.3
Inj. site Tenderness for CYD dengue; Post-Inj. 124.9—
Grd 3 Inj. site Tenderness, CYD dengue; Post-Inj 10.0—
Inj. site Tenderness for placebo; Post-Inj. 1—19.7
Grd 3 Inj. site Tenderness, placebo; Post-Inj. 1—0.3
Inj. site Erythema for Stamaril®; Post-Inj. 18.39.8
Grd 3 Inj.site Erythema for Stamaril®; Post-Inj. 10.00.0
Inj. site Erythema for CYD dengue; Post-Inj. 18.8—
Grd 3 Inj. site Erythema, CYD dengue; Post-Inj. 10.0—
Inj. site Erythema for placebo; Post-Inj. 1—10.9
Grd 3 Inj. site Erythema for placebo; Post-Inj. 1—0.0
Inj. site Swelling for Stamaril®; Post-Inj. 14.74.4
Grd 3 Inj.site Swelling for Stamaril®; Post-Inj. 10.00.0
Inj. site Swelling for CYD dengue; Post-Inj. 14.7—
Grd 3 Inj. site Swelling, CYD dengue; Post-Inj. 10.0—
Inj. site Swelling for placebo; Post-Inj. 1—4.9
Grd 3 Inj. site Swelling for placebo; Post-Inj. 1—0.0
Inj. site Tenderness for CYD dengue; Post-Inj. 217.020.4
Grd 3 Inj. site Tenderness, CYD dengue; Post-Inj 20.00.0
Inj. site Erythema for CYD dengue; Post-Inj. 25.18.0
Grd 3 Inj. site Erythema, CYD dengue; Post-Inj. 20.00.0
Inj. site Swelling for CYD dengue; Post-Inj. 22.74.7
Grd 3 Inj. site Swelling, CYD dengue; Post-Inj. 20.00.0
Inj. site Tenderness for CYD dengue; Post-Inj. 314.616.3
Grd 3 Inj. site Tenderness, CYD dengue; Post-Inj 30.30.0
Inj. site Erythema for CYD dengue; Post-Inj. 33.64.2
Grd 3 Inj. site Erythema, CYD dengue; Post-Inj. 30.00.0
Inj. site Swelling for CYD dengue; Post-Inj. 31.62.8
Grd 3 Inj. site Swelling, CYD dengue; Post-Inj. 30.00.0
Fever; Post-Any Injection48.140.3
Grade 3 Fever; Post-Any Injection1.30.8
Vomiting; Post-Any Injection30.627.2
Grade 3 Vomiting; Post-Any Injection1.32.1
Crying abnormal; Post-Any Injection47.244.0
Grade 3 Crying abnormal; Post-Any Injection0.51.3
Drowsiness; Post-Any Injection36.333.9
Grade 3 Drowsiness; Post-Any Injection0.50.0
Appetite lost; Post-Any Injection54.750.0
Grade 3 Appetite lost; Post-Any Injection4.73.6
Irritability; Post-Any Injection46.446.4
Grade 3 Irritability; Post-Any Injection1.61.6
Fever; Post-Injection 126.716.5
Grade 3 Fever; Post-Injection 11.10.3
Vomiting; Post-Injection 116.117.1
Grade 3 Vomiting; Post-Injection 10.51.0
Crying abnormal; Post-Injection 132.932.1
Grade 3 Crying abnormal; Post-Injection 10.51.3
Drowsiness; Post-Injection 124.422.0
Grade 3 Drowsiness; Post-Injection 10.50.0
Appetite lost; Post-Injection 139.633.7
Grade 3 Appetite lost; Post-Injection 14.43.1
Irritability; Post-Injection 138.634.7
Grade 3 Irritability; Post-Injection 11.61.3
Fever; Post-Injection 221.222.2
Grade 3 Fever; Post-Injection 20.00.3
Vomiting; Post-Injection 212.48.8
Grade 3 Vomiting; Post-Injection 20.50.6
Crying abnormal; Post-Injection 219.721.8
Grade 3 Crying abnormal; Post-Injection 20.00.0
Drowsiness; Post-Injection 212.716.5
Grade 3 Drowsiness; Post-Injection 20.00.0
Appetite lost; Post-Injection 227.023.1
Grade 3 Appetite lost; Post-Injection 20.30.3
Irritability; Post-Injection 217.322.3
Grade 3 Irritability; Post-Injection 20.00.0
Fever; Post-Injection 320.317.8
Grade 3 Fever; Post-Injection 30.30.3
Vomiting; Post-Injection 37.47.3
Grade 3 Vomiting; Post-Injection 30.30.6
Crying abnormal; Post-Injection 315.114.6
Grade 3 Crying abnormal; Post-Injection 30.00.0
Drowsiness; Post-Injection 311.310.7
Grade 3 Drowsiness; Post-Injection 30.00.0
Appetite lost; Post-Injection 319.818.6
Grade 3 Appetite lost; Post-Injection 30.00.3
Irritability; Post-Injection 314.316.1
Grade 3 Irritability; Post-Injection 30.00.3

Adverse events

Collected over Adverse events (AE) were collected from Day 0 (post-vaccination) of Month 0 up to 6 months post-Injection 3 (up to 573 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CYD Dengue Vaccine Group0/394 (0%)35/394 (8.9%)211/394 (53.6%)
Placebo Group1/393 (0.3%)38/393 (9.7%)193/393 (49.1%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCYD Dengue Vaccine GroupPlacebo Group
PneumoniaInfections and infestations12/39411/393
Febrile convulsionNervous system disorders6/3944/393
Urinary tract infectionInfections and infestations4/3943/393
GastroenteritisInfections and infestations0/3942/393
Acute sinusitisInfections and infestations2/3941/393
CellulitisInfections and infestations2/3941/393
Thermal burnInjury, poisoning and procedural complications0/3941/393
Tongue injuryInjury, poisoning and procedural complications0/3941/393
Traumatic brain injuryInjury, poisoning and procedural complications0/3941/393
Acute lymphocytic leukemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3941/393
Most frequent other events
Showing 10 of 19
Most frequent other events
EventCYD Dengue Vaccine GroupPlacebo Group
Appetite lost; Post-Any injectionMetabolism and nutrition disorders211/394193/393
Fever; Post-Any InjectionGeneral disorders185/385155/385
Crying abnormal; Post-Any injectionPsychiatric disorders182/394170/393
Irritability; Post-Any injectionPsychiatric disorders179/394179/393
Injection site Tenderness for CYD dengue vaccine; Post-Any InjectionGeneral disorders141/386105/363
Drowsiness; Post-Any InjectionNervous system disorders140/386131/386
Vomiting; Post-Any injectionGastrointestinal disorders118/386105/386
NasopharyngitisInfections and infestations118/394120/393
Injection site Tenderness for Stamaril® vaccine; Post-Any InjectionGeneral disorders98/38668/386
Injection site Tenderness for placebo; Post-Any InjectionGeneral disorders0/39476/386

Baseline characteristics

Analysis was performed on Safety Analysis Set which included all participants who had received at least 1 dose of CYD dengue vaccine, stamaril® vaccine or placebo.

Age, Categorical
Age, Categorical(Participants)CYD Dengue Vaccine GroupPlacebo GroupTotal
<=18 years394393787
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(Months)CYD Dengue Vaccine GroupPlacebo GroupTotal
Mean12.2 ± 0.2512.2 ± 0.2512.2 ± 0.25
Sex: Female, Male
Sex: Female, Male(Participants)CYD Dengue Vaccine GroupPlacebo GroupTotal
Female198203401
Male196190386
09

Study locations

2 sites
  • Cali, Colombia
  • Lima, Peru
10

References and documents

Related links

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2011 to primary completion in Sep 2013, 24 months.

Results were first posted in Jul 2019, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2011
First posted
Sep 19, 2011
StartActual
Sep 7, 2011
Primary completionActual
Sep 2013
CompletionActual
Sep 2, 2013
Results first posted
Jul 29, 2019
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01436396
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
Sep 7, 2011
Primary completion
Sep 2013
Completion
Sep 2, 2013
Results posted
Jul 29, 2019
Last update
Mar 25, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yellow Fever Vaccine

Start the discussion